AzTrials
AzTrials

Prurigo NodularisPhase 2NCT03816891

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

A Phase 2 study testing Vixarelimab in people with Prurigo Nodularis and Pruritis, run by Genentech, Inc. at 86 sites in 13 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN). Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Prurigo Nodularis, Pruritis
What is being tested?
Vixarelimab
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
240 participants
Where
86 sitesin 13 countries
Study dates
11 Mar 2019to 24 Aug 2023
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Inclusion Criteria (apply to both Phase 2a and Phase 2b unless otherwise specified):

  1. Male or female aged 18 to 75 years (Phase 2a), 18 to 80 years (Phase 2b)
  2. Have clinical diagnosis of prurigo nodularis for at least 6 months
  3. Have at least 10 nodules (Phase 2a), 20 nodules (Phase 2b) at the Screening Visit and Day 1
  4. Moderate to severe pruritus (Phase 2a); severe pruritus (Phase 2b)
  5. Female subjects of childbearing potential must have a negative pregnancy test, be nonlactating, and having agreed to use a highly effective method of contraception, as specified in the protocol, from the Screening Visit until 16 weeks after final study drug administration
  6. Able to comprehend and willing to sign an Informed Consent Form and able to abide by the study restrictions and comply with all study procedures for the duration of the study

Exclusion Criteria (apply to both Phase 2a and Phase 2b unless otherwise specified):

  1. Use of prohibited medications within the indicated timeframe from Day 1
  2. Is currently using medication known to cause pruritus
  3. Presence of any inflammatory, pruritic, and/or fibrotic skin condition other than moderate to severe prurigo nodularis or atopic dermatitis unless approved by the Sponsor
  4. Laboratory abnormalities that fall outside the windows specified in the protocol at the Screening Visit
  5. Has an active infection, including skin infection
  6. Any medical or psychiatric condition which, in the opinion of the Investigator or the Sponsor, may place the subject at increased risk as a result of study participation, interfere with study participation or study assessments, affect compliance with study requirements, or complicate interpretation of study results

Trial locations and contacts

86 sites in 13 countries.

86 sites in 13 countries

United States40 sites
  • ALLCUTIS Research, LLC

    Beverly, Massachusetts, 01915

  • Colorado Center for Dermatology, PLLC

    Centennial, Colorado, 80111

  • Medical University of South Carolina, Department of Dermatology and Dermatological Surgery

    Charleston, South Carolina, 29425

  • Michigan Center for Skin Care Research

    Clinton Township, Michigan, 48038

  • Wright State Physicians

    Fairborn, Ohio, 45324

  • Hamzavi Dermatology

    Fort Gratiot, Michigan, 48059

  • Rybear, Inc.

    Fort Lauderdale, Florida, 33316

  • First OC Dermatology

    Fountain Valley, California, 92708

  • Center for Dermatology Clinical Research, Inc.

    Fremont, California, 94538

  • University of Florida, Department of Dermatology

    Gainesville, Florida, 32610

  • Olympian Clinical Research

    Largo, Florida, 33770

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205

  • Dermatology Research Associates

    Los Angeles, California, 90045

  • Wallace Medical Group, Inc.

    Los Angeles, California, 90056

  • DS Research

    Louisville, Kentucky, 40241

  • ActivMed Practices & Research, Inc.

    Methuen, Massachusetts, 01844

  • University of Miami Itch Center

    Miami, Florida, 33136

  • DS Research

    New Albany, Indiana, 47150

  • Bobby Buka MD, PC

    New York, New York, 10012

  • Velocity Clinical Research - North Hollywood

    North Hollywood, California, 91606

  • Skin Specialists, PC

    Omaha, Nebraska, 68144

  • Riverchase Dermatology

    Pembroke Pines, Florida, 33028

  • Austin Institute for Clinical Research, Inc.

    Pflugerville, Texas, 78660

  • Paddington Testing Co., Inc.

    Philadelphia, Pennsylvania, 19103

  • Arizona Research Center

    Phoenix, Arizona, 85053

  • University of Rochester Dermatology at College Town

    Rochester, New York, 14620

  • Progressive Clinical Research, PA

    San Antonio, Texas, 78213

  • Advanced Medical Research PC

    Sandy Springs, Georgia, 30328

  • Investigate MD, LLC

    Scottsdale, Arizona, 85255

  • Dermatology Specialists of Spokane

    Spokane, Washington, 99202

  • Olympian Clinical Research

    St. Petersburg, Florida, 33709

  • Advanced Clinical Research Institute

    Tampa, Florida, 33607

  • Palm Harbor Dermatology

    Tampa, Florida, 33609

  • Olympian Clinical Research

    Tampa, Florida, 33614

  • Alliance Clinical Research of Tampa

    Tampa, Florida, 33615

  • Somerset Skin Centre

    Troy, Michigan, 48084

  • Grekin Skin Institute

    Warren, Michigan, 08088

  • George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia, 20037

  • Integrated Clinical Research

    West Palm Beach, Florida, 33406

Other trials in United States

Canada8 sites
  • SimcoDerm Medical and Surgical Dermatology Center

    Barrie, Ontario, L4M 7G1

  • Stratica Medical

    Edmonton, Alberta, T5K 1X3

  • Alberta DermaSurgery Centre

    Edmonton, Alberta, T6G 1C3

  • Brunswick Dermatology Center

    Fredericton, New Brunswick, E3B 1G9

  • DermEffects

    London, Ontario, N6H 5L5

  • Lynderm Research Inc.

    Markham, Ontario, L3P 1X2

  • Central Alberta Research Clinic (CARe Clinic)

    Red Deer, Alberta, T4N6V7

  • Drc Angélique Gagné-Henley MD Inc.

    Saint-Jérôme, Quebec, J7Z 7E2

Other trials in Canada

Germany8 sites
  • Fachklinik Bad Bentheim

    Bad Bentheim, Lower Saxony, 48455

  • Klinikum Bielefeld Rosenhöhe

    Bielefeld, North Rhine-Westphalia, 33647

  • University Hospital Dresden

    Dresden, 01307

  • Studienzentrale Entzündliche Hauterkrankungen

    Erlangen, 91054

  • George-August-Universität Göttingen

    Göttingen, 37075

  • University Hospital Muenster, Department of Dermatology

    Münster, 48149

  • Eberhard-Karls-University

    Tübingen, 72076

  • Hautarztpraxis Dr. Hoffmann

    Witten, 58453

Other trials in Germany

Australia4 sites
  • Premier Specialists Pty Ltd

    Kogarah, New South Wales, 2217

  • St. George Dermatology & Skin Cancer Centre

    Kogarah, New South Wales, 2217

  • The Royal Melbourne Hospital

    Parkville, Victoria, 3050

  • Veracity Clinical Research

    Woolloongabba, Queensland, 4102

Other trials in Australia

South Korea4 sites
  • The Catholic University of Korea, Incheon St. Mary's Hospital

    Incheon, 21431

  • Seoul National University Hospital

    Seoul, 03080

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722

  • Asan Medical Center

    Seoul, 05505

Other trials in South Korea

Taiwan4 sites
  • Taipei Medical University Shuang Ho Hospital, Ministry of Health and Welfare

    New Taipei City, 23561

  • National Taiwan University Hospital

    Taipei, 10002

  • Taipei Veterans General Hospital

    Taipei, 11217

  • Chang Gung Memorial Hospital

    Taoyuan City, 333

Other trials in Taiwan

United Kingdom4 sites
  • Royal Infirmary of Edinburgh at Little France

    Edinburgh, EH16 4SA

  • Barts Health NHS Trust, Whipps Cross Hospital

    Leytonstone, E11 1NR

  • Broadgreen Hospital

    Liverpool, L14 3AB

  • University Hospital Southampton NHS Foundation Trust

    Southampton, SO16 6YD

Other trials in United Kingdom

France3 sites
  • Hôpital Saint André - CHU de Bordeaux

    Bordeaux, 33075

  • Hôpital Morvan - CHU Brest

    Brest, 29609

  • CHU Nantes - Service de Dermatologie

    Nantes, 44093

Other trials in France

Poland3 sites
  • Grażyna Pulka Centrum Medyczne All-Med

    Krakow, 30-033

  • Kliniczny Szpital Wojewódzki Nr 1 im. Fryderyka Chopina w Rzeszowie, Klinika Dermatologii

    Rzeszów, 35-055

  • Kyclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska

    Wroclaw, 50-367

Other trials in Poland

Austria2 sites
  • Medical University of Graz

    Graz, 8036

  • Medical University of Vienna

    Vienna, 1090

Other trials in Austria

Belgium2 sites
  • Cliniques Universitaires Saint-Luc (UCL St-Luc)

    Brussels, 1200

  • CHU de Liège

    Liège, 4000

Other trials in Belgium

Czechia2 sites
  • CCR Czech a.s.

    Pardubice, 53 002

  • CLINTRIAL s.r.o.

    Prague, 10000

Other trials in Czechia

Italy2 sites
  • Asst Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

    Brescia, 25123

  • A.O.U. Policlinico Vittorio Emanuele

    Catania, Sicily, 95123

Other trials in Italy

About this study

Official title: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis

Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN).

Read the detailed description

This is a Phase 2a/b randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK and immunogenicity of Vixarelimab administered subcutaneously (SC) in subjects with prurigo nodularis experiencing pruritus.

Phase 2a portion:

Forty-nine subjects with moderate to severe PN experiencing moderate to severe pruritus are treated in the Phase 2a portion of the study. At Baseline, subjects are randomized 1:1 to receive double-blind (DBL) vixarelimab or placebo: vixarelimab 720 mg loading dose followed by 360 mg every week; placebo loading dose followed by placebo every week. The treatment period is 8 weeks or 16 weeks (treatment duration was reduced from 16 weeks to 8 weeks in a protocol amendment [Protocol Version 3]).

Phase 2b portion:

The Phase 2b study consists of a 4-week Screening Period and a 16-week Double-Blind Period, followed by a 36-week Open-Label-Extension (OLE) Period. Approximately 180 subjects with PN, experiencing severe pruritus, are randomized (at 1:1:1:1 ratio) into one of 4 arms (3 active arms and one placebo arm). A total of 4 doses of study drug are administered during the Double-Blind Period to measure the efficacy, safety, and PK of Vixarelimab. After the Double-Blind Period, all subjects have the option to receive vixarelimab during the OLE Period to evaluate the long-term safety and PK.

Being tested
Vixarelimab, Placebo
Medical subject headings
Pruritus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VixarelimabDrug

    Also called KPL-716, RG6536

    solution for injection

  • PlaceboDrug

    solution for injection

Study groups in NCT03816891
Study groupRoleWhat they receive
Phase 2a - Vixarelimab 360 mg SC Weekly (QW)ExperimentalVixarelimab 720 mg loading dose followed by 360 mg weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
Receives: Drug: Vixarelimab
Phase 2a - Placebo SC QWPlacebo comparatorPlacebo loading dose followed by placebo weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
Receives: Drug: Placebo
Phase 2b - Vixarelimab 540 mg SC Every 4 Weeks (Q4W; DBL)ExperimentalVixarelimab 540 mg SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period
Receives: Drug: Vixarelimab
Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL)ExperimentalVixarelimab 360 mg SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period
Receives: Drug: Vixarelimab
Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL)ExperimentalVixarelimab 120 mg SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period
Receives: Drug: Vixarelimab
Phase 2b - Placebo SC, Q4W (DBL)Placebo comparatorPlacebo SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period
Receives: Drug: Placebo
Phase 2b - Vixarelimab 360 mg SC, Every 2 Weeks (Q2W; OLE)ExperimentalVixarelimab 360 mg SC, every 2 weeks for 36 weeks during Open Label Extension
Receives: Drug: Vixarelimab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score

    Participants rated pruritus daily on the Worst Itch [pruritis] Numeric Rating Scale (WI-NRS: 0=no pruritus; 10=worst imaginable pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: at Week 8 (Phase 2a); at Week 16 (Phase 2b)

Secondary outcomes (38)
  1. Phase 2a: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS at Week 8

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).

    Measured: Baseline, Week 8

  2. Phase 2a: Percent Change From Baseline in Pruritus Visual Analog Scale (VAS) at Week 8

    At every visit, participants rated the intensity of their average pruritus over previous 3 days on VAS 0-10 line scale (0=no pruritis, 10=worst imaginable pruritis)

    Measured: Baseline, Week 8

  3. Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over Time

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24

  4. Phase 2a: Percent Change From Baseline in Weekly Average of WI-NRS Over Time

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24

  5. Phase 2a: Change From Baseline in Pruritis Visual Analog Scale (VAS) Over Time

    Participants rated intensity of their average pruritus over previous 3 days on VAS 0-10 line scale (0=no pruritis, 10=worst imaginable pruritis)

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 24

  6. Phase 2a: Percent Change From Baseline in Pruritis Visual Analog Scale (VAS) Over Time

    Participants rated intensity of their average pruritus over previous 3 days on VAS 0-10 line scale (0=no pruritis, 10=worst imaginable pruritis). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 24

  7. Phase 2a: Change From Baseline in 5-D Pruritus Total Score Over Time

    Administered every 2 visits, the 5-D Pruritus Scale evaluates pruritus in 5 domains: duration, degree, direction, disability and distribution. The scores from each domain are added together to obtain a total 5-D score ranging from 5 (no pruritus) to 25 (most severe pruritus).

    Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24

  8. Phase 2a: Percent Change From Baseline in 5-D Pruritus Total Score Over Time

    Administered every 2 visits, the 5-D Pruritus Scale evaluates pruritus in five domains: duration, degree, direction, disability and distribution. The scores from each domain are added together to obtain a total 5-D score ranging from 5 (no pruritus) to 25 (most severe pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24

  9. Phase 2a: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS Over Time

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24

  10. Phase 2a: Change From Baseline in Sleep Loss VAS Over Time

    Participants rated intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness).

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24

  11. Phase 2a: Percent Change From Baseline in Sleep Loss VAS Over Time

    Participants rated intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24

  12. Phase 2a: Change From Baseline in Weekly Average of Difficulty Falling Asleep NRS Over Time

    Participants rate difficulty falling asleep daily on Numerical Rating Scale (0=no difficulty, 10=extremely difficult).

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24

  13. Phase 2a: Percent Change From Baseline in Weekly Average of Difficulty Falling Asleep NRS Over Time

    Participants rate difficulty falling asleep daily on Numerical Rating Scale (0=no difficulty, 10=extremely difficult). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24

  14. Phase 2a: Change From Baseline in Weekly Average of Sleep Quality NRS Over Time

    Participants rated daily sleep quality on Numerical Rating Scale (0=best possible sleep, 10=worst possible sleep).

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24

  15. Phase 2a: Percent Change From Baseline in Weekly Average of Sleep Quality NRS Over Time

    Participants rated daily sleep quality on Numerical Rating Scale (0=best possible sleep, 10=worst possible sleep). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24

  16. Phase 2a: Change From Baseline in Quality of Life (QoL) Measure Dermatology QoL Index (DLQI) Over Time

    QoL was assessed at designated visits and includes the DLQI whereby 0=no effect on quality of life; 30= extremely large effect on QoL.

    Measured: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24

  17. Phase 2a: Percent Change From Baseline in QoL Measure DLQI Over Time

    QoL was assessed at designated visits and includes the DLQI whereby 0=no effect on quality of life; 30= extremely large effect on QoL.

    Measured: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24

  18. Phase 2a: Change From Baseline in QoL Measure Itchy Quality of Life (ItchyQoL) Over Time

    ItchyQoL focuses on impact of pruritus on daily activities and on the level of psychological stress. It contains 22 items. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered). The recall period in ItchyQoL is the past week. The ItchyQoL total score is defined as the sum of all 22-items scores. Total scores can be classified as little (0-30), mild (31-50), moderate (51-80), and severe (81-110).

    Measured: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24

  19. Phase 2a: Percent Change From Baseline in QoL Measure Itchy QoL Over Time

    ItchyQoL focuses on impact of pruritus on daily activities and on the level of psychological stress. It contains 22 items. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered). The recall period in ItchyQoL is the past week. The ItchyQoL total score is defined as the sum of all 22-items scores. Total scores can be classified as little (0-30), mild (31-50), moderate (51-80), and severe (81-110). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24

  20. Phase 2a: Change From Baseline in Prurigo Nodularis Nodule Assessment Tool (PN-NAT) Over Time: Number of Nodules Over the Whole Body Score

    PN-NAT, assessed at designated visits, is a novel exploratory tool for the evaluation of disease severity based on estimate of the number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriation over the whole body, distribution of nodules, exact number of nodules in the representative area. The first three components (number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriations over the whole body) were analyzed as secondary endpoints. For the Number of Nodules over the Whole Body score: 0=0 nodules; 1=1 to 9 nodules; 2=10 to 50 nodules; and 3=more than 50 nodules. A higher score indicates worse disease.

    Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24

  21. Phase 2a: Change From Baseline in PN-NAT Over Time: Estimate of Hardness of Nodules Over the Whole Body

    PN-NAT, assessed at designated visits, is a novel exploratory tool for the evaluation of disease severity based on estimate of the number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriation over the whole body, distribution of nodules, exact number of nodules in the representative area. The first three components (number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriations over the whole body) were analyzed as secondary endpoints. For the Estimate of Hardness of Nodules Over the Whole Body score: 0=No nodules are hard; 1=Up to one-third of nodules are hard; 2=One-third to two-thirds of nodules are hard; and 3=More than two-thirds of nodules are hard. A higher score indicates worse disease.

    Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24

  22. Phase 2a: Change From Baseline in PN-NAT Over Time: Extent of Excoriations Over the Whole Body

    PN-NAT, assessed at designated visits, is a novel exploratory tool for the evaluation of disease severity based on estimate of the number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriation over the whole body, distribution of nodules, exact number of nodules in the representative area. The first three components (number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriations over the whole body) were analyzed as secondary endpoints. For the Extent of Excoriations over the Whole Body score: 0=No nodules are excoriated; 1=Up to one-third of nodules are excoriated; 2=One-third to two-thirds of nodules are excoriated; and 3=More than two-thirds of nodules are excoriated. A higher score indicates worse disease.

    Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24

  23. Phase 2a: Percentage of Participants With Improvement in Prurigo Nodularis Investigator Global Assessment (PN-IGA) by 2 Categories Over Time

    PN-IGA, assessed at designated visits, is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the presence/absence of nodules and the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease).

    Measured: Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24

  24. Phase 2b: Percentage of Participants Achieving at Least a 6-Point Reduction From Baseline in Weekly Average WI-NRS at Week 16

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (0=no pruritus; 10=worst imaginable pruritus).

    Measured: Baseline, Week 16

  25. Phase 2b: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS at Week 16

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (0=no pruritus; 10=worst imaginable pruritus).

    Measured: Baseline, Week 16

  26. Phase 2b: Percentage of Participants Achieving a Score of 0 or 1 in PN-IGA at Week 16

    PN-IGA, assessed at designated visits, is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the presence/absence of nodules and the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease); 0 (clear) indicates no nodules and 1 (almost clear) indicates nodules are present, few of the nodules are moderately raised.

    Measured: Week 16

  27. Phase 2b: Change From Baseline in Weekly Average of WI-NRS Over Time

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 1 through 52

  28. Phase 2b: Percent Change From Baseline in Weekly Average of WI-NRS Over Time

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 1 through 52

  29. Phase 2b: Percentage of Participants Achieving at Least a 6-Point Reduction From Baseline in Weekly Average WI-NRS Over Time

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).

    Measured: Baseline, Weeks 1 through 52

  30. Phase 2b: Percentage of Participants Achieving at Least a 4-Point Reduction From Baseline in Weekly Average WI-NRS Over Time

    Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).

    Measured: Baseline, Weeks 1 through 52

  31. Phase 2b: Percentage of Participants Achieving 0 or 1 in PN-IGA Over Time

    PN-IGA is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the presence/absence of nodules and the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease); 0 (clear) indicates no nodules and 1 (almost clear) indicates nodules are present, few of the nodules are moderately raised.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52

  32. Phase 2b: Percentage of Participants With at Least 2-Point Improvement From Baseline in PN-IGA Over Time

    PN-IGA is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease).

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52

  33. Phase 2b: Percentage of Participants Achieving 0 (Clear) or 1 (Almost Clear) in Investigator's Global Assessment for Prurigo Nodularis-Stage (IGA-CNPG-S) Over Time

    IGA-CNPG-S is a novel tool for the investigator assessment of PN disease severity based on the number of palpable nodules and utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe); 0 (clear) indicates no nodules and 1 (almost clear) indicates rare palpable pruriginous nodules (approximately 1-5 nodules). A score is assigned based on the appearance of the disease at the time of the evaluation without referring to the baseline state.

    Measured: Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52

  34. Phase 2b: Percentage of Participants With at Least 2-point Improvement From Baseline in IGA-CNPG-S Over Time

    IGA-CNPG-S, administered at designated visits, is a novel tool for the investigator assessment of PN disease severity based on the number of palpable nodules and utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe). A score is assigned based on the appearance of the disease at the time of the evaluation without referring to the baseline state.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52

  35. Phase 2b: Change From Baseline in Weekly Average of Sleep Loss VAS Over Time

    Participants rated intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness). A score was set to missing after a participant received prohibited/rescue medication that potentially impact efficacy analyses prior to Week 16, and the participant's worst post baseline observation before the time of the medication usage was carried forward (WOCF) to impute missing endpoint value (for participants whose postbaseline values were all missing, the baseline was used to impute). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52

  36. Phase 2b: Percent Change From Baseline in Weekly Average of Sleep Loss VAS Over Time

    Participants rated intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness). A score was set to missing after a participant received prohibited/rescue medication that potentially impact efficacy analyses prior to Week 16, and the participant's worst post baseline observation before the time of the medication usage was carried forward (WOCF) to impute missing endpoint value (for participants whose postbaseline values were all missing, the baseline was used to impute). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52

  37. Phase 2b: Change From Baseline in ItchyQoL Over Time

    ItchyQoL focuses on impact of pruritus on daily activities and on the level of psychological stress. It contains 22 items. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered). The recall period in ItchyQoL is the past week. The ItchyQoL total score is defined as the sum of all 22-items scores. Total scores can be classified as little (0-30), mild (31-50), moderate (51-80), and severe (81-110). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 4, 8, 12, 16, 18, 20, 32, 48, 52

  38. Phase 2b: Percent Change From Baseline in ItchyQoL Over Time

    ItchyQoL focuses on impact of pruritus on daily activities and on the level of psychological stress. It contains 22 items. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered). The recall period in ItchyQoL is the past week. The ItchyQoL total score is defined as the sum of all 22-items scores. Total scores can be classified as little (0-30), mild (31-50), moderate (51-80), and severe (81-110). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.

    Measured: Baseline, Weeks 4, 8, 12, 16, 18, 20, 32, 48, 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jan 2019
  2. Study start11 Mar 2019
  3. Primary completion28 Dec 2022
  4. Study completion24 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Phase 2a: 2 arms; Phase 2b: 5 arms (4 arms during Double Blind Period and 1 arm during Open Label Extension)
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
240 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03816891
Sponsor's protocol ID
KPL-716-C201
Other IDs
GS45044
Status last verified
Jan 2026
First submitted
23 Jan 2019
Last updated
13 Jan 2026
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Stander S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF. Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial. JAMA Dermatol. 2026 Feb 1;162(2):133-141. doi: 10.1001/jamadermatol.2025.4950.

    PubMed 41405882
  • Ma DX, Neerumalla S, Baird A, Whitehead RA, Filip P, Tajudeen BA, Batra PS, Papagiannopoulos P. Impact of Obesity on the Structured Histopathology of Chronic Rhinosinusitis Patients. Laryngoscope. 2026 Mar;136(3):1150-1157. doi: 10.1002/lary.70177. Epub 2025 Oct 6.

    PubMed 41051123
  • Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. eCollection 2023 Mar.

    PubMed 36816342

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Vixarelimab in people with Prurigo Nodularis and Pruritis, run by Genentech, Inc. at 86 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 86 sites in United States, Canada, Germany, Australia, South Korea and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Jan 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score (time frame: at Week 8 (Phase 2a); at Week 16 (Phase 2b)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03816891, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in